128 related articles for article (PubMed ID: 22440786)
1. Enduring response to everolimus as third-line therapy in a patient with advanced renal cell carcinoma, including small-bowel metastases: loss of FHIT but normal VHL gene status.
Broom RJ; Caldwell I; Hanning F; Fong P; Deva S; Oei P
Clin Genitourin Cancer; 2012 Sep; 10(3):202-6. PubMed ID: 22440786
[No Abstract] [Full Text] [Related]
2. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic studies of 24 renal epithelial tumors with von Hippel-Lindau and fragile histidine triad protein expression correlation.
Gayrard N; Cacheux V; Iborra F; Mourad G; Argilés A
Arch Pathol Lab Med; 2008 Jun; 132(6):965-73. PubMed ID: 18517280
[TBL] [Abstract][Full Text] [Related]
4. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
5. [Genetic backgrounds of renal cell carcinoma].
Oya M
Nihon Rinsho; 2006 Feb; 64 Suppl 2():593-6. PubMed ID: 16523961
[No Abstract] [Full Text] [Related]
6. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma.
Sükösd F; Kuroda N; Beothe T; Kaur AP; Kovacs G
Cancer Res; 2003 Jan; 63(2):455-7. PubMed ID: 12543802
[TBL] [Abstract][Full Text] [Related]
7. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease.
Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H
Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476
[TBL] [Abstract][Full Text] [Related]
8. Analysis of molecular cytogenetic changes in metastatic renal cell carcinoma in the setting of everolimus treatment: a pilot project.
Caldwell IR; Oei P; Ng D; Caudwell B; Fong PC; Broom RJ
Clin Genitourin Cancer; 2014 Aug; 12(4):256-61. PubMed ID: 24524969
[TBL] [Abstract][Full Text] [Related]
9. A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma.
Poland KS; Azim M; Folsom M; Goldfarb R; Naeem R; Korch C; Drabkin HA; Gemmill RM; Plon SE
Genes Chromosomes Cancer; 2007 Sep; 46(9):805-12. PubMed ID: 17539022
[TBL] [Abstract][Full Text] [Related]
10. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
[TBL] [Abstract][Full Text] [Related]
11. Targeting von Hippel-Lindau pathway in renal cell carcinoma.
Patel PH; Chadalavada RS; Chaganti RS; Motzer RJ
Clin Cancer Res; 2006 Dec; 12(24):7215-20. PubMed ID: 17189392
[TBL] [Abstract][Full Text] [Related]
12. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance.
Velickovic M; Delahunt B; Störkel S; Grebem SK
Cancer Res; 2001 Jun; 61(12):4815-9. PubMed ID: 11406557
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.
Damiano V; Rosa R; Formisano L; Nappi L; Gelardi T; Marciano R; Cozzolino I; Troncone G; Agrawal S; Veneziani BM; De Placido S; Bianco R; Tortora G
Br J Cancer; 2013 Apr; 108(8):1616-23. PubMed ID: 23571736
[TBL] [Abstract][Full Text] [Related]
14. About the origin and development of hereditary conventional renal cell carcinoma in a four-generation t(3;8)(p14.1;q24.23) family.
Valle L; Cascón A; Melchor L; Otero I; Rodríguez-Perales S; Sánchez L; Cruz Cigudosa J; Robledo M; Weber B; Urioste M; Benítez J
Eur J Hum Genet; 2005 May; 13(5):570-8. PubMed ID: 15756303
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
Paule B; Brion N
Anticancer Res; 2011 Oct; 31(10):3507-10. PubMed ID: 21965770
[TBL] [Abstract][Full Text] [Related]
16. [Development of human renal cell carcinoma (RCC)--the responsible genes for the development of hereditary and sporadic human RCCs].
Shuin T; Kamata M; Ashida S
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1719-25. PubMed ID: 12402420
[TBL] [Abstract][Full Text] [Related]
17. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
19. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.
Sutphin PD; Chan DA; Li JM; Turcotte S; Krieg AJ; Giaccia AJ
Cancer Res; 2007 Jun; 67(12):5896-905. PubMed ID: 17575159
[TBL] [Abstract][Full Text] [Related]
20. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
[No Abstract] [Full Text] [Related]
[Next] [New Search]
